JBJeffrey C. Bassett

Jeffrey C. Bassett

*This is an algorithmically generated author record based on publicly available information.

Jeffrey C. Bassett has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Single-Port Retzius-Sparing Robot-Assisted Radical Prostatectomy: Feasibility and Early Outcomes

    by Jeffrey C. Bassett, Salpi Salibian, Simone Crivellaro

    BACKGROUND Determine safety and feasibility of single-port, Retzius-sparing robot-assisted radical prostatectomy (SP-rsRARP) using the da Vinci® SP (Intuitive Surgical, Sunnyvale, CA, USA) robotic platform in men with adenocarcinoma of the prostate. PATEINTS AND METHODS Twenty-eight consecutive men with prostate cancer underwent SP-rsRARP by one of two surgeons (J.B., S.C.). Data for peri-operative, pathologic, and functional outcomes were collected prospectively and retrospectively analyzed. RESULTS Mean (SD) follow-up was 6 (3) months. Mean age was 65.3 years old with an average body mass index of 25.2 kg/m2. Mean preoperative PSA was 10.2 ng/mL. Average prostate weight was 42 grams. Three patients (11%) had prior radiation to the prostate. There were no intraoperative complications or conversions of technique. Lymphadenectomy was performed in twenty-four (86%) patients and nerve-sparing in fourteen (46%). Mean operative time (skin to skin) was 234 minutes with an average estimated blood loss of 148 mL. Length of hospital stay averaged 23 hours. Seventeen (61%) of the patients did not require opioids for post-operative pain. Two Clavien Grade IIIa complications occurred (lymphocele aspiration, dilation of bladder neck contracture). Pathological grade group was group 1 (0%), grade 2 (57%), group 3 (29%) and group 4-5 (14%). Pathologic stage was T2 (15/28, 54%) and T3a,b (13/28, 46%). Five patients (18%) had a positive surgical margin, four (80%) of whom had T3 disease. One patient (4%) had a detectable PSA in follow-up and opted for adjuvant radiation. Twenty-three patients (82%) were continent at foley removal. Post-operative mean SHIM scores in those who underwent nerve-sparing was 18 at 3-months follow-up. CONCLUSIONS SP-rsRARP appears safe and feasible. Early continence rates are promising. Full characterization of outcomes require longer follow-up and larger cohort validation.


  • Open Access

    PD23-11 VARIATION IN EVALUATION OF HEMATURIA BY GENDER, RACE, AND RISK FACTORS FOR BLADDER CANCER

    by Jacob Ark, JoAnn Alvarez, Jeffrey Bassett, Tatsuki Koyama, Chaochen You, Shenghua Ni, William Blot, David Penson, Daniel Barocas


  • Open Access

    Quality of diagnostic staging in patients with bladder cancer: A process‐outcomes link

    by Karim Chamie, Eric Ballon‐Landa, Jeffrey C. Bassett, Timothy J. Daskivich, Meryl Leventhal, Dennis Deapen, Mark S. Litwin

    BACKGROUND: Muscle sampling is often used as a surrogate for staging quality in patients with bladder cancer. The association of staging quality at diagnosis and survival was examined among patients with bladder cancer.METHODS: The clinical records of all individuals within the Los Angeles Surveillance, Epidemiology, and End Results registry with an incident diagnosis of non–muscle‐invasive bladder cancer in 2004‐2005 were reviewed. Patient demographics, tumor characteristics, staging quality (presence of muscle in the specimen and mention of muscle in the pathology report), and vital status were recorded. With mixed‐effects and competing‐risks regression analyses, the association of patient and tumor characteristics with staging quality and cancer‐specific survival was quantified.RESULTS: The sample included 1865 patients, 335 urologists, and 27 pathologists. Muscle was reported to be present in 972 (52.1%), was reported to be absent in 564 (30.2%), and was not mentioned in 329 (17.7%) of the initial pathology reports. The presence of muscle did not differ according to the grade or depth of invasion. Mortality was associated with staging quality (P < .05). Among patients with high‐grade disease, the 5‐year cancer‐specific mortality rates were 7.6%, 12.1%, and 18.8% when muscle was present, absent, and not mentioned, respectively.CONCLUSIONS: The omission of muscle in the specimen or its mention in the pathology report in nearly half of all diagnostic resections was associated with increased mortality, particularly in patients with high‐grade disease. Because urologists cannot reliably discern between high‐ and low‐grade or Ta and T1 disease, it is contended that patients with bladder cancer should undergo adequate muscle sampling at the time of endoscopic resection. Cancer 2015;121:379–385. © 2014 American Cancer Society.


  • Variation in the Intensity of Hematuria Evaluation: A Target for Primary Care Quality Improvement

    by David F. Friedlander, Matthew J. Resnick, Chaochen You, Jeffrey Bassett, Vidhush Yarlagadda, David F. Penson, Daniel A. Barocas


  • A 60-Year-Old Man With Gross Hematuria and Flank Pain

    by Eric T. Miller, William J. Aronson, Jeffrey C. Bassett


  • Developments and controversies in the management of noninvasive bladder cancer

    by Jeffrey C. Bassett, John B. Eifler, Matthew J. Resnick, Peter E. Clark

    To summarize recent developments and controversies in the diagnosis and management of nonmuscle invasive bladder cancer (NMIBC). The majority of incident bladder cancer diagnoses are noninvasive. The mainstay of diagnosis remains cystoscopy and transurethral resection, with enhanced optical techniques potentially improving detection of nascent disease. Intravesical chemotherapeutic and immunotherapeutic agents reduce the likelihood of recurrence and progression, with novel agents showing promise. The identification of variant histology with aggressive phenotypes permits identification of patients unlikely to respond to intravesical agents, in whom early cystectomy is advocated. Risk stratification of patients with NMIBC continues to improve and should be used to inform surveillance and treatment paradigms. Tobacco cessation may improve disease-specific endpoints and overall mortality. NMIBC encompasses a variety of tumors with heterogeneous natural histories, making clinical management challenging. Improved detection with novel technologies and optimization of existing treatment modalities hold promise of improving oncologic outcomes in the future.

  • MP6-16 GENDER, RACE, AND VARIATION IN THE WORKUP OF HEMATURIA

    by Jeffrey Bassett, JoAnn Alvarez, Chaochen You, Tatsuki Koyama, Shenghua Ni, David Penson, Daniel Barocas

  • MP2-01 TREATMENT PATTERNS IN PATIENTS WITH RECURRENT HIGH-RISK BLADDER CANCER

    by Karim Chamie, Eric Ballon-Landa, Jeffrey C. Bassett, Timothy J. Daskivich, Julie Lai, Jan M. Hanley, Badrinath R. Konety, Mark S. Litwin, Christopher S. Saigal

  • Top Cited Papers
    Open Access

    Recurrence of high‐risk bladder cancer: A population‐based analysis

    by Karim Chamie, Mark S. Litwin, Jeffrey C. Bassett, Timothy J. Daskivich, Julie Lai, Jan M. Hanley, Badrinath R. Konety, Christopher S. Saigal, The Urologic Diseases In America Project

    BACKGROUND: Patients with bladder cancer are apt to develop multiple recurrences that require intervention. The recurrence, progression, and bladder cancer–related mortality rates were examined in a cohort of individuals with high‐grade non–muscle‐invasive bladder cancer.METHODS: Using linked Surveillance, Epidemiology, and End Results (SEER)‐Medicare data, subjects were identified who had a diagnosis of high‐grade, non–muscle‐invasive disease in 1992 to 2002 and who were followed until 2007. Multivariate competing‐risks regression analyses were then used to examine recurrence, progression, and bladder cancer–related mortality rates.RESULTS: Of 7410 subjects, 2897 (39.1%) experienced a recurrence without progression, 2449 (33.0%) experienced disease progression, of whom 981 succumbed to bladder cancer. Using competing‐risks regression analysis, the 10‐year recurrence, progression, and bladder cancer–related mortality rates were found to be 74.3%, 33.3%, and 12.3%, respectively. Stage T1 was the only variable associated with a higher rate of recurrence. Women, black race, undifferentiated grade, and stage Tis and T1 were associated with a higher risk of progression and mortality. Advanced age (≥ 70) was associated with a higher risk of bladder cancer–related mortality.CONCLUSIONS: Nearly three‐fourths of patients diagnosed with high‐risk bladder cancer will recur, progress, or die within 10 years of their diagnosis. Even though most patients do not die of bladder cancer, the vast majority endures the morbidity of recurrence and progression of their cancer. Increasing efforts should be made to offer patients intravesical therapy with the goal of minimizing the incidence of recurrences. Furthermore, the high recurrence rate seen during the first 2 years of diagnosis warrants an intense surveillance schedule. Cancer 2013;119:3219–3227. © 2013 American Cancer Society.